Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Sinonasal Sarcomas Management: An International Consensus Statement
Caspani, F , Camarda, Anna Maria , Provenzano, Salvatore , Meço, Cem , Ferrari, Marco , Harrabi, Semi , Hosni, Ali, Italiano, Antoine, Vérillaud, Benjamin , Castelnuovo, Paolo, Nicolai, Piero, Su, Shirley Y. , Eloy, Jean Anderson , Fiore, Maria Rosaria, Palmer, James, Oliden, Victor Castro , Tos, Angelo Paolo Dei , Casali, Paolo G. , Dufresne, Armelle , Orlandi, Ester , Wormald, Peter‐John, Herman, Philippe , Carrau, Ricardo, Hanna, Ehab Y., Provenzano, Salvatore , Wang, Eric W , Ferrari, Marco , Schreiber, Alberto , Lechner, Matt , Eloy, Jean Anderson , Georgalas, Christos , Turri-Zanoni, Mario , Meço, Cem , Su, Shirley Y , Vinciguerra, Alessandro , Valentini, Marco , Šurda, Pavol , Campos, Fernando Augusto Batista , Martín‐Broto, Javier , Guadagnolo, B. Ashleigh , Navarria, Pierina , Hindi, Nadia , Italiano, Antoîne , Trifiletti, Daniel M. , Kasper, Bernd , Schreiber, Alberto , Castelnuovo, Paolo, Nicolai, Piero , Dallan, Iacopo , Chacón, Matías , Thariat, Juliette , Valverde, Claudia María , Lechner, Matt , Blay, Jean‐Yves , Brahmi, Mehdi , Greto, Daniela , Lugowska, Iwona A. , van Zele, Thibaut , Psaltis, Alkis J. , Sangalli, Claudia , Wormald, Peter‐John , Hanna, Ehab Y., Licitra, Lisa , Turri‐Zanoni, Mario , Battaglia, Paolo

Mayo Clinic

International Forum of Allergy & Rhinology | September 30, 2025 | Volume: 16 | Issue: 1 | Pages: 55-69

10.1002/alr.70038 | PMID 41025537 Get It

ABSTRACT Introduction Sinonasal sarcomas are exceedingly rare entities, constituting less than 7% of head and neck sarcomas. Their complex histology needs specialized treatment, which is often based on multimodal approaches including surgery, radiation therapy, and/or chemotherapy. This manuscript aims to gather expert opinions to establish common management principles for sinonasal sarcomas. Methods This international consensus followed a modified Delphi method in seven steps, including statements definition by the core group, expert panel recruitment, and a two‐round survey. Sixty‐two statements on sinonasal sarcoma management were developed. Experts from multiple continents participated, and results were anonymized and analyzed between March and May 2025. Results A total of 44 invited experts were recruited, 43.2% otorhinolaryngologists/head and neck surgeons, 31.8% medical oncologists, and 25% radiation oncologists. Participants varied in age and experience, representing Europe (70.5%), North America (18.2%), South America (6.8%), and Asia (4.5%). Among all histologies, biphenotypic sarcoma, chondrosarcoma, leiomyosarcoma, and myofibrosarcoma are principally treated with an upfront surgical management, differently from Ewing sarcoma and rhabdomyosarcoma in which chemotherapy, eventually associated with radiotherapy, is often chosen. In the remaining histologies (angiosarcoma, liposarcoma, malignant peripheral nerve sheath tumor [MPNST], osteosarcoma, and synovial sarcoma), a precise multimodal treatment is less standardized and needs to be discussed on a case‐by‐case basis. Conclusion Sinonasal sarcomas require a histology‐driven approach to determine upfront treatment, whether surgical, medical, or multimodal. Despite this structured strategy, prognosis remains highly variable across subtypes. Multidisciplinary evaluation and individualized management in referral centers are crucial to address the biological diversity and anatomical complexity of these rare malignancies.
Suicide Interventions for Youths
Sim, Leslie , McKean, Alastair J. , Mohammed, Khaled , Rajjo, Tamim , Simha, Suvyaktha, Fleti, Farah, Hegazi, Mustafa, Abusalih, Mohamed , Al-Kordi, Mohammad, Basmaci, Rami, Chuzhyk, Olena, Saadi, Samer , Farah, Magdoleen H. , Viola, Kelly E., Mohammed, Khaled S, Rajjo, Tamim I, Abusalih, Mohamed E, Hasan, Bashar , Saadi, Samer , Farah, Magdoleen H , Abusalih, Mohamed , Murad, M. Hassan , Croarkin, Paul E. , Firwana, Mohammed , Hasan, Bashar, Prokop, Larry J. , Wang, Zhen

Mayo Clinic

JAMA Pediatrics | September 29, 2025 | Volume: 179 | Issue: 11 | Pages: 1217

10.1001/jamapediatrics.2025.3485 | PMID 41021221 Get It

Importance Suicide is a leading cause of death among young people and an escalating public health crisis. Objective To assess the effectiveness and harms of available treatments for suicidal thoughts and behaviors among youths at heightened risk for suicide. Evidence Review A systematic review was conducted searching databases including MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus, and various gray literature sources from January 1, 2000, to September 26, 2024. We included randomized clinical trials, comparative observational studies, and before-after studies of psychosocial interventions, pharmacologic interventions, neurotherapeutics, emerging therapies, and combination therapies. Eligible patients were youths (aged 5-24 years) with heightened risk for suicide, adolescents from racial and ethnic minority groups known to be at increased risk of suicide, or those exposed to crime or violence. Pairs of independent reviewers selected and appraised studies. Findings This review included 65 studies (33 randomized clinical trials, 13 comparative observational studies, and 19 before-after studies) reporting on 14 534 patients (median age, 15.1 years; 75.1% female patients). Psychosocial interventions comprised psychotherapy interventions (33 studies; cognitive behavioral therapy, dialectical behavioral therapy, collaborative assessment and management of suicidality, dynamic deconstructive psychotherapy, attachment-based family therapy, and family-focused therapy), acute (ie, 1-4 sessions or contacts) psychosocial interventions (19 studies; safety planning, family-based crisis management, motivational interviewing crisis interventions, continuity of care after crisis, and brief adjunctive treatments), and school- or community-based psychosocial interventions (13 studies; social network interventions, school-based skills interventions, suicide awareness or gatekeeper programs, and community-based, culturally tailored adjunct programs). Dialectical behavior therapy showed moderate strength of evidence for reducing suicidal ideation. Other categories of psychosocial treatments showed insufficient to low strength of evidence for reducing suicidal outcomes. None of the studies evaluated adverse events. The evidence base on pharmacologic treatment for youths at risk of suicide was largely nonexistent. Conclusions and Relevance This systematic review found that the current evidence on available interventions targeting youths at heightened risk of suicide is uncertain. Medication, neurotherapeutics, and emerging therapies remain unstudied among this population. The limited evidence base calls for the development of novel, developmentally and trauma-informed treatments, as well as multilevel interventions to target the increasing suicide risk among youths.
Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target
Mun, Dong‐Gi , Jessen, Erik , Carlson, Danielle M. , Watkins, Ryan , Gregory, Lindsey A., McCabe, Chantal E. , Golkowski, Martin , Baker, Marshall S., Conboy, Caitlin B. , Ozmert, Enis H., Kandasamy, Richard K. , Roberts, Lewis R. , Andersen, Joshua L. , Smoot, Rory L. , Tomlinson, Jennifer L. , Abdelrahman, Amro , Gregory, Lindsey, Conboy, Caitlin, Larson, Ellen L. , Roberts, Lewis, Pandey, Akhilesh , Jessen, Erik , Roberts, Lewis R , Smoot, Rory L , Kandasamy, Richard K , Conboy, Caitlin B , Mun, Dong-Gi , Carlson, Danielle Marie , Budhraja, Rohit , Alva‐Ruiz, Roberto , Abdelrahman, Amro M. , Wang, Chen , Graham, Rondell P. , Woods, Kathryn, Gores, Gregory J. , Ilyas, Sumera I. , Sample, Jack W. , Borad, Mitesh J. , Pandey, Akhilesh

Mayo Clinic

Hepatology | September 29, 2025 | Volume: 84 | Issue: 2 | Pages: 396-410

10.1097/hep.0000000000001535 | PMID 41020779 Get It

Background and Aims: Cholangiocarcinoma (CCA) is one of the most lethal cancers, characterized by molecular heterogeneity and treatment resistance. To uncover new biological signals and therapeutic opportunities, we employed multiomic characterization combined with machine learning. Approach and Results: We profiled all anatomical CCA subtypes using whole exome sequencing, mRNA sequencing, and proteome/phosphoproteome analysis. Integrative dimensional reduction revealed RNA, protein, and phosphoprotein features driving tumor heterogeneity, enabling clustering. Machine learning algorithms identified molecular features for each cluster and mapped external datasets and patient-derived xenograft (PDX) models onto these clusters. Kinase enrichment analysis highlighted targetable kinases active in each cluster. In vivo validation was performed in cluster-specific PDX models using the selective TNK1 inhibitor, TP-5801. We identified 3 molecular clusters with distinct pathway characterization: immunomodulatory (cluster 1), metabolic (cluster 2), and gene regulation/cellular fate (cluster 3). Cluster assignment was independent of anatomic subtype but correlated with overall survival following curative-intent resection. We also identified multiomic features and pathways linked to overall survival and lymph node metastases, crucial for patient treatment selection. Kinase enrichment analysis pinpointed TNK1 as a highly active kinase in the metabolic cluster. Treatment with TP-5801 significantly reduced tumor growth in a metabolic PDX model, but not in models representing the other clusters. Combining internal data with publicly available datasets, we identified the immunomodulatory cluster as most responsive to gemcitabine/cisplatin therapy, confirmed in vivo using cluster-specific PDX models. Conclusions: Integrated multiomic characterization provides translational insights by defining unique molecular subtypes associated both with therapeutic response and overall clinical outcomes. This approach identified TNK1 as a previously unrecognized therapeutic target in a defined subset of CCA tumors.
The Relationship Between Non-Invasive Tests and Digital Pathology for Quantifying Liver Fibrosis in MASLD
Wei, Xiaodie , Qiu, Lixia , Wang, Xinxin , Shao, Chen , Zhao, Jing , Chen, Jun , Yin, Meng , Ehman, Richard L. , Zhang, Jing , Yin, Meng , Ehman, Richard , Yang, Qiang

Mayo Clinic

Diagnostics | September 29, 2025 | Volume: 15 | Issue: 19 | Pages: 2475

10.3390/diagnostics15192475 | PMID 41095694 Get It

Background: It is crucial to evaluate liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Digital pathology, an automated method for quantitative fibrosis measurement, provides valuable support to pathologists by providing refined continuous metrics and addressing inter-observer variability. Although non-invasive tests (NITs) have been validated as consistent with manual pathology, the relationship between digital pathology and NITs remains unexplored. Methods: This study included 99 biopsy-proven MASLD patients. Quantitative-fibrosis (Q-Fibrosis) used second-harmonic generation/two-photon excitation fluorescence microscopy (SHG/TPEF) to quantify fibrosis parameters (q-FPs). Correlations between eight NITs and q-FPs were analyzed. Results: Using manual pathology as standard, Q-Fibrosis exhibited excellent diagnostic performance in fibrosis stages assessment with area under the receiver operating characteristic curves (AUCs) ranging from 0.924 to 0.967. In addition, magnetic resonance elastography (MRE) achieved the highest diagnostic accuracy (AUC: 0.781–0.977) among the eight NITs. Furthermore, MRE-assessed liver stiffness measurement (MRE-LSM) showed the strongest correlation with q-FPs, particularly adjusted by string length, string width, and the number of short and thick strings within the portal region. Conclusions: Both MRE and digital pathology demonstrated excellent diagnostic accuracy. MRE-LSM was primarily determined by collagen extent, location and pattern, which provide a new perspective for understanding the relationship between the change in MRE and histological fibrosis reverse.
Cerebrospinal fluid cell-free DNA as a liquid biopsy tool for detecting and monitoring genomic alterations in thalamic colorectal cancer metastases
Loron, Ali Gharibi , Ha, Yooree , Riviere-Cazaux, Cécile , Warrington, Arthur E. , Gharibi Loron, Ali, Wang, Xiaohong , Burns, Terry C.

Mayo Clinic

Neuro-Oncology Advances | September 29, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf178 | PMID 41323961 Get It

Abstract Background Cerebrospinal fluid cell-free DNA (cfDNA) can detect and monitor leptomeningeal disease but has not been previously used to monitor parenchymal lesions. Methods Herein, we report our initial experience with CSF cfDNA monitoring for 2 patients with colorectal cancer (CRC) metastases to the thalamus, causing obstructive hydrocephalus. Results CSF samples were obtained during ventriculoperitoneal shunt placement, demonstrating high levels of cfDNA in both cases. Several genomic alterations detected in the cfDNA sequencing matched those in the tumor tissue biopsy. Follow-up CSF evaluations after subsequent therapy were used to help adjudicate pseudo-progression versus true progression. Conclusions Neither patient developed leptomeningeal disease, demonstrating CSF’s utility in evaluating solitary brain metastases in direct contact with a CSF compartment.
Large language models for bioinformatics
Ruan, Wei, Lyu, Yanjun , Zhang, Jing , Cai, Jiazhang , Lu, Yao , Wang, Tao , Liu, Yufang , Fang, Luyang , Liu, Ziyu , Liu, Zhengliang , Li, Yiwei , Wu, Zihao , Chen, Junhao , Jiang, Hanqi, Yang, Zhenyuan, Liang, Shizhe, Zhang, Wei , Ma, Terry, Dou, Yuan , Zhang, Jianli , Gong, Xinyu , Gan, Qi , Zou, Yusong , Chen, Z. J. , Qian, Yuanxin, Yu, Shuo , Song, Kenan, Sikora, Andrea, Li, Xiang , Wang, Yingfeng , Zhong, Wenxuan, Liu, Rongjie , Huang, Chao , Shen, Ye , Yan, Yajun , Liu, Tianming, Huang, Chao , Song, Kenan , Wang, Peilong, Chen, Jingyuan, Song, Kenan , Ruan, Wei, Shu, Peng , Yang, Ge , Gao, Shang , Wang, Yue , Wang, Peilong , Zhao, Lin , Jiang, Hanqi , Pan, Yi Feng , Chen, Jingyuan , Dou, Yuan, Chen, Z. J. , Qian, Yuanxin, Jin, Lu , Wang, Xianqiao , Sikora, Andrea , Li, Gang , Li, Quanzheng , Zhang, Lu, Abate, Yohannes , He, Lifang , Zhong, Wenxuan, Liu, Wei , Ma, Ping , Zhu, Hongtu , Zhu, Dajiang

Mayo Clinic

Quantitative Biology | September 29, 2025 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/qub2.70014 | PMID 41676319 Get It

Abstract With the rapid advancements in large language model technology and the emergence of bioinformatics‐specific language models (BioLMs), there is a growing need for a comprehensive analysis of the current landscape, computational characteristics, and diverse applications. This survey aims to address this need by providing a thorough review of BioLMs, focusing on their evolution, classification, and distinguishing features, alongside a detailed examination of training methodologies, datasets, and evaluation frameworks. We explore the wide‐ranging applications of BioLMs in critical areas such as disease diagnosis, drug discovery, and vaccine development, highlighting their impact and transformative potential in bioinformatics. We identify key challenges and limitations inherent in BioLMs, including data privacy and security concerns, interpretability issues, biases in training data and model outputs, and domain adaptation complexities. Finally, we highlight emerging trends and future directions, offering valuable insights to guide researchers and clinicians toward advancing BioLMs for increasingly sophisticated biological and clinical applications.
Poster 27: Arthroscopic Labral Repair Results in Lower Recurrence Rates and Is Highly Cost-Effective When Compared to Nonoperative Management for Primary Anterior Shoulder Dislocations: A Contemporary Systematic Review and Decision-Analytic Markov Model-Ba
Oeding, Jacob F., Schulz, William, Wang, Allen S., Krych, Aaron J., Taylor, Dean C., Samuelsson, Kristian, Camp, Christopher L., Tagliero, Adam J., Oeding, Jacob F., Schulz, William, Wang, Allen S., Krych, Aaron J., Taylor, Dean C., Samuelsson, Kristian, Camp, Christopher L., Tagliero, Adam J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00139 Get It

Objectives: Value based decision making regarding nonoperative management vs. early surgical stabilization for first-time anterior shoulder instability (ASI) events remains controversial. Thus, the purpose of this study was to perform 1) a systematic review of the current literature and 2) a Markov model-based cost-effectiveness analysis comparing an initial trial of nonoperative management to arthroscopic Bankart repair (ABR) for first-time ASI. Methods: A Markov Chain Monte Carlo probabilistic model (Figure 1) was developed to evaluate the outcomes and costs of 1,000 simulated patients (average age » 20 years old) with first-time ASI undergoing nonoperative management vs. ABR. Utility values, recurrence rates, and transition probabilities were derived from the published literature. Costs were determined based on the typical patient undergoing each treatment strategy at our institution. Outcome measures included costs, quality-adjust life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). Probabilities of recurrence as well as the utility of each treatment strategy were obtained from the literature search as described above. Probabilities were pooled across studies to obtain a weighted average for both nonoperative treatment and ABR. Similarly, studies reporting scores on the Western Ontario Shoulder Instability Index (WOSI) scale were utilized to approximate shoulder-related quality of life after each treatment strategy and outcome. Costs for each treatment strategy and transition state in the model were considered from the payer perspective (commercial or government) and obtained from institutional data at a large, academic medical center. Results: The Markov model with Monte Carlo microsimulation demonstrated average (± standard deviation) costs for nonoperative management and ABR of $38,649 ± 10,521 and $43,052 ± 9,352, respectively. Total QALYS acquired over the 10-year time horizon were 7.7 ± 0.4 and 8.4 ± 0.5 for nonoperative management and ABR, respectively. The ICER comparing ABR to nonoperative management was found to be just $5,725/QALY, which falls substantially below the $50,000 willingness-to-pay (WTP) threshold (Figure 2). The mean number of recurrences were 2.6 ± 0.3 and 1.2 ± 0.2 for patients initially assigned to the nonoperative and ABR treatment groups, respectively. Out of 1,000 samples run over 1,000 trials, ABR was the optimal strategy in 98.7% of cases, with nonoperative management the optimal strategy in 1.3% of cases (Figure 3). Conclusions: The primary findings of this systematic review and cost-effectiveness analysis were as follows: 1) when compared to nonoperative management, arthroscopic Bankart repair (ABR) substantially reduces the risk of recurrent dislocations, 2) ABR results in greater shoulder function and higher WOSI scores than does nonoperative management, and 3) despite substantially higher upfront costs, ABR proved to be more cost-effective than an initial trial of nonoperative management, which can be attributed to both fewer recurrent dislocations and greater utility over the long-term.
Advancing delirium detection through the Open Health Natural Language Processing Consortium and the Evolve to Next-Gen Accrual to Clinical Trials Network
Fu, Sunyang , Kwak, Min Ji , Ahn, Jaerong, Yue, Zhiyi , Ranganath, Shreyas, Applegate, Joseph R., Wang, Liwei , Li, Chenyu , Toth, Kelly M, Girard, Timothy D., Osborne, John D. , Kennedy, Richard , Garduno-Rapp, Nelly-Estefanie, Reeder, Phillip , Murphy, Thomas J. , Heling, Jia, Sohn, Sunghwan , Visweswaran, Shyam, Wang, Yanshan , Girard, Timothy D. , Li, Chenyu , Rousseau, Justin F , Yan, Chao , Murphy, Tyler J , Park, Chan Mi , Bernstam, Elmer V , Visweswaran, Shyam , Liu, Hongfang , Girard, Timothy D , Fu, Sunyang , Kennedy, Richard E , Osborne, John D , Wang, Yanshan , Ahn, Jaerong, Applegate, Joseph R, Wen, Andrew , Morris, Michele M. , Toth, Kelly M, Rousseau, Justin F. , Chen, You , Patel, Mayur Bipin , Malin, Bradley , Jia, Heling, Pagali, Sandeep R. , Palmer, Allyson K. , Sauver, Jennifer L. St. , Liu, Hongfang

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | September 26, 2025 | Volume: 80 | Issue: 12 | Pages: No page available

10.1093/gerona/glaf207 | PMID 41017643 Get It

Abstract Background Delirium is often underdiagnosed in clinical practice and is not routinely coded for billing. While manual chart review can identify delirium, it is labor-intensive and impractical for large-scale studies. Natural language processing (NLP) can analyze unstructured text in electronic health records (EHRs) to extract meaningful clinical information. Methods To support national integration of NLP for EHR-based delirium identification across different institutions, we launched the Delirium Interest Group within the national Evolve to Next-Gen Accrual to Clinical Trials (ENACT) NLP Working Group. This paper outlines our initial efforts to standardize, evaluate, and translate an NLP-based delirium detection model into the i2b2/ENACT platform. Results Multisite contextual inquiry identified several key challenges, including variations in local screening practices (eg, tools used, documentation frequency, and quality control), the need for harmonized definitions in the context of EHRs, and the complexity of modeling temporal logic. Multisite NLP evaluation revealed variable performance degradation driven by differences in delirium screening practices, clinical documentation patterns and semantics, and note syntactic structures. Conclusion Our work represents an important first step toward enabling scalable and standardized NLP-based delirium detection across institutions. By engaging diverse institutions through the ENACT NLP Working Group, we identified shared challenges and site-specific variations that impact model implementation and performance. Our collaborative approach enabled the development of a more robust framework for delirium identification across heterogeneous EHR systems. Future efforts will build on this foundation to enhance the validity, usability, and translational impact of delirium detection.
Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML
Wang, Eunice S. , Montesinos, Pau , Foran, James M. , Erba, Harry P. , Rodríguez‐Arbolí, Eduardo , Fedorov, Kateryna, Heiblig, Maël , Heidel, Florian H. , Altman, Jessica K. , Baer, Maria R. , Pettit, Kristen , Papayannidis, Cristina , Walter, Roland B. , Khawandanah, Mohamad , Garcia, Olga Salamero, Bergeron, Julie , Ulrickson, Matthew L. , Redner, Robert L. , McCloskey, James, Pigneux, Arnaud , Fuente, Adolfo de la , Mitra, Amitava , Soifer, Harris S. , Tabachri, Marilyn, Zhang, Zijing , Riches, Marcie , Corum, Daniel, Leoni, Mollie , Barabé, Frédéric , Bergeron, Julie, Castillo, Teresa Bernal del, Berthon, Céline, Elsawy, Mahmoud , Reyner, Jordi Esteve, Fedorov, Kateryna, Giannini, Caterina, Heiblig, Maël, Issa, Ghayas C., Penedo, Agustín, Garcia, Olga Salamero, Ulrickson, Matthew, Venditti, Adriano , Walter, Roland B., Wang, Eunice S., Foran, James M , Erba, Harry Paul , Peterlin, Pierre , Berthon, Céline , Walter, Roland B , Shah, Mithun V , Balasubramanian, Suresh , Khawandanah, Mohamad , Bergeron, Julie , Roboz, Gail J , Ulrickson, Matthew , Pigneux, Arnaud , de la Fuente Burguera, Adolfo , Issa, Ghayas , Fathi, Amir T , Wang, Eunice S. , Montesinos, Pau , Pettit, Kristen , Papayannidis, Cristina , Heiblig, Mael , Fedorov, Kateryna, Adès, Lionel , Shah, Meera , Garcia, Olga Salamero, Madanat, Yazan F. , Roboz, Gail J. , Castillo, Teresa Bernal del, Deeren, Dries , Esteve, Jordi , Fedorov, Kateryna, Heiblig, Maël, Issa, Ghayas C., Lanza, Francesco , Garcia, Olga Salamero, Schwarzer, Adrian , Ulrickson, Matthew, Walter, Roland B., Wang, Eunice S.

Mayo Clinic

Journal of Clinical Oncology | September 25, 2025 | Volume: 43 | Issue: 31 | Pages: 3381-3390

10.1200/jco-25-01694 | PMID 40997296 Get It

PURPOSE Ziftomenib—a potent, highly selective, oral menin inhibitor—was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1 -mutated ( NPM1 -m) and KMT2A -rearranged AML in the KOMET-001 phase I trial. METHODS In the registration-enabling phase II part of KOMET-001, patients with relapsed/refractory NPM1 -m AML received ziftomenib 600 mg once daily. The primary end point was the rate of complete remission with full hematologic recovery (CR)/CR with partial hematologic recovery (CRh). RESULTS From January 26, 2023, to May 13, 2024, 92 patients (median age, 69 years [range, 33-84]) were treated. The primary end point was met, with a CR/CRh rate of 22% (95% CI, 14 to 32; P = .0058); 61% were negative for measurable residual disease. Overall response rate was 33% (95% CI, 23 to 43), with a median duration of 4.6 months (95% CI, 2.8 to 7.4). Prespecified subgroup analyses showed comparable CR/CRh regardless of previous therapy, including venetoclax, or type of comutations. Median overall survival was 6.6 months (95% CI, 3.6 to 8.6). Common grade ≥3 treatment-emergent adverse events were febrile neutropenia (26%), anemia (20%), and thrombocytopenia (20%). Differentiation syndrome occurred in 25% of patients (15% grade 3; no grade 4-5) and was manageable with protocol-defined mitigation. Three patients (3%) discontinued treatment because of ziftomenib-related adverse events. CONCLUSION Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory NPM1 -m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.
CD1d+ Goblet Cells Expand Colon-Resident Immature, Intermediate and Differentiated iNKT Cells to Limit Colitis
Newberry, Rodney D. , John, Vini , Barrios, Bibiana E., Wang, Jacqueline D. , Udayan, Sreeram , Floyd, Alexandria N., Joyce, Elisabeth L, Sundas, Shushma, McDonald, Keely G. , Blumberg, Richard S. , Hsieh, Chyi, Rusconi, Brigida , Wang, Jacqueline D , Udayan, Sreeram , Mavers, Melissa , Blumberg, Richard S , Rusconi, Brigida , Newberry, Rodney D , Knoop, Kathryn A. , Schill, Ellen Merrick , Jayasinghe, Reyka G.

Mayo Clinic

No container title available | September 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7603392/v1 | PMID 41041542 Get It

Abstract Invariant Natural Killer T (iNKT) cells recognize glycolipid antigens presented on CD1d and rapidily respond to direct immune responses. iNKT cells develop in the thymus and migrate to peripheral tissues in what has been presumed to be differentiated/committed states. Accordingly, colonic iNKT cells are established in early life, considered to remain ‘fixed’ post-weaning, and determine life-long colitis susceptibility. Using single cell RNA sequencing (scRNA-seq), we demonstrate that humans and mice contain colonic iNKT populations transcriptionally resembling immature and intermediate thymic iNKT precursors. Contrary to prevailing paradigms, we demonstrate colonic iNKT cell populations expand in adult mice when CD1d expressing colonic goblet cells form goblet cell-associated antigen passages. Expansion preferentially affected intermediate iNKT cells, was durable, and protective in a colitis model. These studies reveal that the adult colon harbors iNKT cells with retained plasticity and uncover a novel role for goblet cells as unconventional antigen presenting cells regulating this axis.